Want to see XNCR full AI Analyst Report?
XNCR Stock Chart & Stats
$28.44
$0.42(2.16%)
At close: 4:00 PM EDT
$28.44
$0.42(2.16%)
Day’s Range― - ―
52-Week Range$9.80 - $30.61
Previous Close$19.86
Volume942.30K
Average Volume (3M)1.29M
Market Cap
$1.84B
Enterprise Value$934.98
Total Cash (Recent Filing)$456.45M
Total Debt (Recent Filing)$65.21M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 09, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding74,353,390
10 Day Avg. Volume1,053,674
30 Day Avg. Volume1,290,290
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.79
Price to Sales (P/S)9.05
P/FCF Ratio-8.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$31.89Price Target Upside12.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.07
Revenue Forecast (FY)$143.94M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a substantial equity cushion provide financial flexibility while Xencor funds clinical development. This reduces balance-sheet pressure and may help the company withstand setbacks or preserve strategic options over the next several quarters.
Extended Operating RunwayThe settlement supplies meaningful capital and extends the period available to advance programs without immediate additional financing. That runway can support development continuity, improve negotiating flexibility, and reduce near-term dilution pressure.
XmAb Platform CapabilityThe XmAb platform offers a reusable engineering foundation across cancer and autoimmune or inflammatory programs. Its ability to modify several antibody attributes can support differentiated candidates and collaboration opportunities beyond any single product.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the company is not yet self-funding its development portfolio. Continued burn can consume the cash cushion, increase dependence on financing or partnerships, and limit investment flexibility.
Weak ProfitabilityLarge losses and negative operating results indicate that current costs remain well above revenue, while negative returns on equity signal ongoing value erosion. Without durable earnings improvement, funding needs and execution risk remain elevated.
Volatile Collaboration RevenueAn uneven, partnership-driven revenue model makes results dependent on the timing of clinical progress, milestones, and royalty-generating products. This volatility complicates planning and leaves revenue less predictable than a recurring product-sales base.
Xencor News
XNCR FAQ
What was Xencor Inc’s price range in the past 12 months?
Xencor Inc lowest stock price was $9.80 and its highest was $30.61 in the past 12 months.
What is Xencor Inc’s market cap?
Xencor Inc’s market cap is $1.84B.
When is Xencor Inc’s upcoming earnings report date?
Xencor Inc’s upcoming earnings report date is Nov 09, 2026 which is in 49 days.
How were Xencor Inc’s earnings last quarter?
Xencor Inc released its earnings results on Aug 05, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.801 by $0.511.
Is Xencor Inc overvalued?
According to Wall Street analysts Xencor Inc’s price is currently Undervalued.
Does Xencor Inc pay dividends?
Xencor Inc does not currently pay dividends.
What is Xencor Inc’s EPS estimate?
Xencor Inc’s EPS estimate is -0.38.
How many shares outstanding does Xencor Inc have?
Xencor Inc has 74,353,390 shares outstanding.
What happened to Xencor Inc’s price movement after its last earnings report?
Xencor Inc reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.801. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Xencor Inc?
Currently, no hedge funds are holding shares in XNCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.89 (12.13% Upside)
$31.89 (12.13% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 75%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 227.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
146.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xencor Inc
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XNCR Stock 12 Month Forecast
Average Price Target
$31.89
▲(12.13% Upside)
Technical Analysis
CytomX Therapeutics
―
AnaptysBio
―
Zymeworks
―
AbCellera Biologics
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.54% Insiders
29.30% Mutual Funds
3.88% Other Institutional Investors
40.14% Public Companies and
Individual Investors